康惠制药:2024年报净利润-0.9亿 同比下降246.15%

Financial Performance - The company reported a basic earnings per share of -0.9000 yuan for 2024, a decrease of 246.15% compared to -0.2600 yuan in 2023 [1] - The total revenue for 2024 was 5.62 billion yuan, down 16.49% from 6.73 billion yuan in 2023 [1] - The net profit for 2024 was -0.9 billion yuan, a significant decline from -0.26 billion yuan in 2023, reflecting a 246.15% decrease [1] - The return on equity for 2024 was -9.92%, compared to -2.72% in 2023, indicating a worsening financial performance [1] Shareholder Structure - The top ten unrestricted shareholders collectively hold 62.08% of the circulating shares, with a decrease of 15.93 thousand shares compared to the previous period [1] - Shaanxi Kanghui Holdings Co., Ltd. remains the largest shareholder with 36.75% of the total share capital, unchanged from the previous report [2] - New entrants among the top shareholders include Shanghai Sailuxian Enterprise Management Consulting Co., Ltd. with 10.00% and Shenwan Li with 1.11% [2] Dividend Distribution - The company has announced no dividend distribution or capital increase for the current reporting period [3]